#SaveTheDate: Join our CEO Mike Weiss for a Fireside Chat during the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3rd at 10:00am ET.?Webcast at: https://lnkd.in/eguXMYM #TGTX #Evercore #FearlessForPatients
TG Therapeutics, Inc.
生物技术研究
New York，NY 29,003 位关注者
TG is a biopharmaceutical company focused on the development of novel treatments for B-cell diseases.
关于我们
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).
- 网站
-
https://www.tgtherapeutics.com/
TG Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- New York，NY
- 类型
- 上市公司
- 创立
- 2011
- 领域
- Biotechnology、hematological malignancies、non-Hodgkin's lymphoma、multiple sclerosis、b-cell diseases、ublituximab和umbralisib
地点
-
主要
获取路线
US，NY，New York，10014
TG Therapeutics, Inc.员工
动态
-
#BreakingNews – TG Therapeutics has been ranked No.1 in the Deloitte 30th Annual Technology #Fast500 list – “honoring the most innovative, fastest-growing companies in North America.” Congratulations #TGTX Team! Details: bit.ly/3Z2CPZk #FearlessForPatients #MS @DeloitteTMT?
-
-
#TGTX Q3 2024 Financial Results have been released! Details: bit.ly/3YPj34L - Join our #Earnings call this morning at 8:30AM ET.?Dial in: 1-877-407-8029 (US), 1-201-689-8029 (Ex-US) Title: TG Q3 2024 – Webcast at: https://lnkd.in/eguXMYM #FearlessForPatients
-
-
#TGTX will host a Q3 2024 Earnings Call on Monday, Nov. 4th, 2024 @ 8:30AM ET. Dial in: 1-877-407-8029 (US), 1-201-689-8029 (Ex-US) Title: TG Q3 2024 - Webcast will be available at: https://lnkd.in/eguXMYM #FearlessForPatients #Earnings
-
-
New data from the ENHANCE Ph 3b study show rapid 30-minute infusions are well tolerated in patients with #RMS. Check out the data: bit.ly/4gmEMrs – #TGTX #ECTRIMS2024 starts today #MS #FearlessForPatients
-
-
New data in #RMS shows 92% of patients free from disability progression after 5 years of treatment.?Check out the data: bit.ly/4e6ssKx – #TGTX #ECTRIMS2024 starts today #MS #FearlessForPatients
-
-
Abstracts are Live! #ECTRIMS2024 Copenhagen, Denmark Sept. 18-20.?#TGTX will share 3 presentations highlighting data in #RMS.?Check out the abstracts: bit.ly/4cOGSxq?Please visit our TG Booth C3-B01 & Business Suite in section B5.?#MS #FearlessForPatients
-
-
#TGTX Q2 2024 Financial Results have been released! Details: bit.ly/4fwkwmR - Join our #Earnings call this morning at 8:30AM ET.?Dial in: 1-877-407-8029 (US), 1-201-689-8029 (Ex-US) Title: TG Q2 2024 – Webcast at: https://lnkd.in/eguXMYM #FearlessForPatients
-
-
#TGTX will host a Q2 2024 Earnings Call on Tues., August 6, 2024 @ 8:30AM ET. Dial in: 1-877-407-8029 (US), 1-201-689-8029 (Ex-US) Title: TG Q2 2024 - Webcast will be available at: https://lnkd.in/eguXMYM #FearlessForPatients #Earnings
-
-
#DontMissIt - Join today’s Fireside Chat with TG CEO Mike Weiss at the Goldman Sachs 45th Annual Global Healthcare Conference 2024 - Tuesday, June 11th @ 1:20PM ET. AudioCast: https://lnkd.in/eC6nRGS #TGTX #FearlessForPatients Goldman Sachs
-